Huifeng Zhang1, Pingshuan Dong1, Xuming Yang1, Zhenghao Liu1. 1. Department of Cardiology, First Affiliated Hospital of Henan University of Science and Technology Luoyang 471003, Henan Province, China.
Abstract
BACKGROUND: The aim of the current study was to evaluate the association of PAI-1 4G/5G polymorphism with coronary artery disease (CAD) risk using a meta-analysis. METHODS: All eligible studies were identified through a search of PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Database of Chinese Scientific and Technical Periodicals, and China Biology Medical literature database (CBM) before June 2014. The association between the PAI-1 4G/5G polymorphism and CAD risk was estimated by odds ratio (OR) and 95% confidence interval (CI). RESULTS: A total of 72 studies including 23557 cases and 21526 controls were eventually collected. The PAI-1 4G/5G polymorphism was significant associated with CAD risk in overall population (OR=1.19, 95% CI 1.10-1.28, P < 0.00001). The combination of adjusted ORs for CAD was 1.20 (95% CI 1.03-1.40, P=0.02). This polymorphism was associated with CAD risk in Caucasians (OR=1.10, 95% CI 1.02-1.19, P=0.01) and Asians (OR=1.46, 95% CI 1.21-1.75, P < 0.0001). This polymorphism significantly increased MI risk (OR=1.15, 95% CI 1.06-1.25, P=0.001). In the subgroup analysis by age, this polymorphism was significantly associated with early-onset CAD risk (OR=1.21, 95% CI 1.02-1.43, P=0.03). In the gender subgroup analyses, a statistically significant association was found in male CAD patients (OR=1.10, 95% CI 1.01-1.20, P=0.04). Both T2DM patients and non-T2DM patients carrying 4G allele showed increased CAD risks (OR=2.23, 95% CI 1.27-3.92, P=0.005 and OR=1.64, 95% CI 1.19-2.25, P=0.002, respectively). CONCLUSIONS: This meta-analysis suggested that PAI-1 4G/5G polymorphism was a risk factor for CAD.
BACKGROUND: The aim of the current study was to evaluate the association of PAI-1 4G/5G polymorphism with coronary artery disease (CAD) risk using a meta-analysis. METHODS: All eligible studies were identified through a search of PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Database of Chinese Scientific and Technical Periodicals, and China Biology Medical literature database (CBM) before June 2014. The association between the PAI-1 4G/5G polymorphism and CAD risk was estimated by odds ratio (OR) and 95% confidence interval (CI). RESULTS: A total of 72 studies including 23557 cases and 21526 controls were eventually collected. The PAI-1 4G/5G polymorphism was significant associated with CAD risk in overall population (OR=1.19, 95% CI 1.10-1.28, P < 0.00001). The combination of adjusted ORs for CAD was 1.20 (95% CI 1.03-1.40, P=0.02). This polymorphism was associated with CAD risk in Caucasians (OR=1.10, 95% CI 1.02-1.19, P=0.01) and Asians (OR=1.46, 95% CI 1.21-1.75, P < 0.0001). This polymorphism significantly increased MI risk (OR=1.15, 95% CI 1.06-1.25, P=0.001). In the subgroup analysis by age, this polymorphism was significantly associated with early-onset CAD risk (OR=1.21, 95% CI 1.02-1.43, P=0.03). In the gender subgroup analyses, a statistically significant association was found in male CAD patients (OR=1.10, 95% CI 1.01-1.20, P=0.04). Both T2DM patients and non-T2DM patients carrying 4G allele showed increased CAD risks (OR=2.23, 95% CI 1.27-3.92, P=0.005 and OR=1.64, 95% CI 1.19-2.25, P=0.002, respectively). CONCLUSIONS: This meta-analysis suggested that PAI-1 4G/5G polymorphism was a risk factor for CAD.
Authors: W C Hooper; C Lally; H Austin; M Renshaw; A Dilley; N K Wenger; D J Phillips; C Whitsett; P Rawlins; B L Evatt Journal: Thromb Res Date: 2000-08-01 Impact factor: 3.944
Authors: I Canavy; M Henry; P E Morange; L Tiret; O Poirier; A Ebagosti; M Bory; I Juhan-Vague Journal: Thromb Haemost Date: 2000-02 Impact factor: 5.249
Authors: J L Anderson; J B Muhlestein; J Habashi; J F Carlquist; T L Bair; S P Elmer; B P Davis Journal: J Am Coll Cardiol Date: 1999-11-15 Impact factor: 24.094
Authors: Esther Zorio; Juan Gilabert-Estellés; Francisco España; Luis A Ramón; Raul Cosín; Amparo Estellés Journal: Curr Med Chem Date: 2008 Impact factor: 4.530
Authors: P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen Journal: J Clin Invest Date: 1993-12 Impact factor: 14.808
Authors: Banu Bayram; Aaron R Owen; Amel Dudakovic; Jacob W Bettencourt; Afton K Limberg; Mark E Morrey; Joaquin Sanchez-Sotelo; Daniel J Berry; Jean-Pierre Kocher; Andre J van Wijnen; Matthew P Abdel Journal: Meta Gene Date: 2021-03-05
Authors: Manal S Fawzy; Eman A Toraih; Nagwa M Aly; Abeer Fakhr-Eldeen; Dahlia I Badran; Mohammad H Hussein Journal: BMC Cardiovasc Disord Date: 2017-01-13 Impact factor: 2.298
Authors: Ameen M Mohammad; Galawezh O Othman; Chiman H Saeed; Sarah Al Allawi; George S Gedeon; Shatha M Qadir; Nasir Al-Allawi Journal: BMC Res Notes Date: 2020-11-24
Authors: Charles Nkansah; Otchere Addai-Mensah; Kofi Mensah; Michael Owusu; Richard K D Ephraim; Patrick Adu; Felix Osei-Boakye; Samuel K Appiah; Dorcas Serwaa; Charles A Derigubah; Alexander Yaw Debrah Journal: PLoS One Date: 2021-04-15 Impact factor: 3.240
Authors: Wisam Jasim Mohammed; Bassam Musa Sadik Al-Musawi; Christian Oberkanins; Helene Pühringer Journal: Int J Health Sci (Qassim) Date: 2018 May-Jun